These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


322 related items for PubMed ID: 12920224

  • 1. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
    Mukunyadzi P, Liu K, Hanna EY, Suen JY, Fan CY.
    Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
    [Abstract] [Full Text] [Related]

  • 2. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
    Mukunyadzi P, Sanderson RD, Fan CY, Smoller BR.
    Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
    [Abstract] [Full Text] [Related]

  • 3. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.
    Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tanaka T, Takamori K, Igawa K, Yoshida M, Fukuyama H, Takahashi T, Sakoda S.
    J Oral Pathol Med; 2006 May; 35(5):301-6. PubMed ID: 16630294
    [Abstract] [Full Text] [Related]

  • 4. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
    Rintala M, Inki P, Klemi P, Jalkanen M, Grénman S.
    Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
    [Abstract] [Full Text] [Related]

  • 5. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
    Anttonen A, Kajanti M, Heikkilä P, Jalkanen M, Joensuu H.
    Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
    [Abstract] [Full Text] [Related]

  • 6. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
    Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC.
    Clin Cancer Res; 2004 Aug 01; 10(15):5178-86. PubMed ID: 15297422
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
    Tsanou E, Ioachim E, Briasoulis E, Charchanti A, Damala K, Karavasilis V, Pavlidis N, Agnantis NJ.
    J Exp Clin Cancer Res; 2004 Dec 01; 23(4):641-50. PubMed ID: 15743035
    [Abstract] [Full Text] [Related]

  • 8. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes.
    Inki P, Larjava H, Haapasalmi K, Miettinen HM, Grenman R, Jalkanen M.
    Eur J Cell Biol; 1994 Feb 01; 63(1):43-51. PubMed ID: 8005104
    [Abstract] [Full Text] [Related]

  • 9. Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis.
    Chen CL, Ou DL.
    Hum Pathol; 2006 Oct 01; 37(10):1279-85. PubMed ID: 16949936
    [Abstract] [Full Text] [Related]

  • 10. Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue.
    Ro Y, Muramatsu T, Shima K, Yajima Y, Shibahara T, Noma H, Shimono M.
    Int J Oral Maxillofac Surg; 2006 Mar 01; 35(3):252-7. PubMed ID: 16280239
    [Abstract] [Full Text] [Related]

  • 11. [The effect of the microenvironment of head and neck cancers on tumor progression].
    Lukits J.
    Magy Onkol; 2009 Mar 01; 53(1):51-9. PubMed ID: 19318327
    [Abstract] [Full Text] [Related]

  • 12. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis.
    Maeda T, Desouky J, Friedl A.
    Oncogene; 2006 Mar 02; 25(9):1408-12. PubMed ID: 16247452
    [Abstract] [Full Text] [Related]

  • 13. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
    Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS.
    Mod Pathol; 2001 Oct 02; 14(10):1052-8. PubMed ID: 11598177
    [Abstract] [Full Text] [Related]

  • 14. Altered expression of syndecan-1 in prostate cancer.
    Kiviniemi J, Kallajoki M, Kujala I, Matikainen MT, Alanen K, Jalkanen M, Salmivirta M.
    APMIS; 2004 Feb 02; 112(2):89-97. PubMed ID: 15056224
    [Abstract] [Full Text] [Related]

  • 15. Syndecan in carcinomas produced from transformed epithelial cells in nude mice.
    Inki P, Kujari H, Jalkanen M.
    Lab Invest; 1992 Mar 02; 66(3):314-23. PubMed ID: 1538586
    [Abstract] [Full Text] [Related]

  • 16. Expression of ets-1 transcription factor in human head and neck squamous cell carcinoma and effect of histamine on metastatic potential of invasive tumor through the regulation of expression of ets-1 and matrix metalloproteinase-3.
    Horváth B, Hegyesi H, Nagy P, Falus A, Schaff Z.
    Head Neck; 2005 Jul 02; 27(7):585-96. PubMed ID: 15887216
    [Abstract] [Full Text] [Related]

  • 17. Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma.
    Muro-Cacho CA, Anderson M, Cordero J, Muñoz-Antonia T.
    Clin Cancer Res; 1999 Jun 02; 5(6):1243-8. PubMed ID: 10389906
    [Abstract] [Full Text] [Related]

  • 18. Developmental and FGF-2-mediated regulation of syndecans (1-4) and glypican in oligodendrocytes.
    Bansal R, Kumar M, Murray K, Pfeiffer SE.
    Mol Cell Neurosci; 1996 Apr 02; 7(4):276-88. PubMed ID: 8793863
    [Abstract] [Full Text] [Related]

  • 19. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
    Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M.
    Cancer Res; 2001 Jul 15; 61(14):5562-9. PubMed ID: 11454708
    [Abstract] [Full Text] [Related]

  • 20. Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas.
    Máthé M, Suba Z, Németh Z, Tátrai P, Füle T, Borgulya G, Barabás J, Kovalszky I.
    Oral Oncol; 2006 May 15; 42(5):493-500. PubMed ID: 16364677
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 17.